What should I do if the Sanyin type breast cancer is metastasized?

三阴性乳腺癌（即ER、PR、HER2表达均为阴性）转移通常也叫做晚期（即存在远处转移）三阴性乳腺癌（通常可以分为初次诊断即为晚期，或者初次诊断非晚期，在Subsequent transfer occurred). The main treatment methods of advanced three -negative breast cancer are still chemotherapy, of course, such as immunotherapy and targeted therapy for BRCA1/2.

01. From the aspect of chemotherapy (chemotherapy)

For patients with metastatic breast cancer who have previously accepted a rings (Table Roubi Star, Dorrabar, Piraceli Star, etc.), chemotherapy (paclitaxel, white protein paclitaxel, etc.) drugs are usually selected. Program. For patients with metastatic breast cancer who failed to accept rings (Table Roubi Star, Dorrabar, Pirathonic Star, etc.) and paclitaxel (paclitaxel, white protein paclitaxel, etc.), the alternative drugs were card Pecarbin, Changchun Ruibin, Ailibarin, platinum chemotherapy drugs, Youdaron and so on.

02. From the perspective of immunotherapy

Previous clinical trials show that PD-L1 inhibitors (such as Ada Lizab) combined with white protein paclitaxel schemes have improved patients' unopened occurrence time, and the application of immunosuppressive agents brings survival benefits to advanced three-negative breast cancer. Optional treatment strategy.

03. From a targeted treatment

For advanced triple -negative breast cancer for BRCA1/2 mutations, the application of PARP inhibitory Ora Pali also improves the patient's unopened occurrence time. The antibody coupling drug (SACITUZUMAB GOVITECAN, SG, Gosha, monoclonal antibody) also brought dawn to the patient's targeted therapy. In addition, the latest research Destiny-Breast04 test shows that in HER2 low expression metastatic breast cancer (it should be noted that patients with triple-negative breast cancer accounted for only about 10%of the study), Dexiustezumabi than Dr. Chemotherapy chosen by Dr. It can make patients get longer progressive survival and overall survival.

In addition, for patients with advanced three -negative breast cancer, the chemotherapy scheme has its own toxic and side effects that cannot be tolerated, and generally do not choose a certain solution for long -term use for maintenance. With the development of precision medicine, the refinement of the typical type of three -negative breast cancer is also possible for the treatment of advanced three -negative breast cancer. Many clinical trials are also in full swing. In the future Treatment in clinical treatment. It should be noted that the choice of the above treatment methods requires patients to have a good physical condition (the supervisor in charge of the doctor will comprehensively comprehensively patients before treatment).

- END -